Martin David Harp

Scott Xiao, co-founder and CEO of Luminopia, sat with Ophthalmology Times to discuss the PUPiL Registry and how the VR treatment for children with amblyopia works and can revolutionize amblyopia treatment.

4D-150 Is being evaluated in wet age-related macular degeneration (AMD).

This marks 21 years in a row the hospital has been top-ranked by the US News & World Report in the field of ophthalmology.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

Most respondents were unsure of how to seek treatment and see dry eye as something that must be learned to live with.

The company states this will enable movement toward US approval

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

Apellis plans to seek re-examination, with a final opinion expected in fourth quarter of 2024.

The biosimilar was approved for treating patients with age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.

Ashley Brissette, MD, MSc, FRCSC, team ophthalmologist for the New York Rangers sat down to talk about eye injuries in hockey and other professional sports, as well as advancements in prevention and treatment for the players.

4D-175 will be evaluated in the GAZE clinical trial, an upcoming phase 1, open-label trial.

Under the new policy, grant-making entities will be encouraged to fund post-market research investigating pharmacodynamics and pharmacokinetics for generic drugs that did not adequately enroll women, and sexual and gender minority populations in their clinical trials.

The trial is designed to enable a resubmission of a New Drug Application to the US FDA for reproxalap after receiving a Complete Response Letter last year.

Two randomized, double-masked, placebo-controlled, Phase 3 trials named REVEAL-1 and REVEAL-2 are expected to start in August 2024.

All R&D for the drug will stop after the Phase 2a clinical trial failed to meet its primary endpoint of lowering IOP in patients with primary open-angle glaucoma.

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

The IND approval will allow the company to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).

The launch of Blink NutriTears follows a clinical trial that demonstrated improved ocular symptom severity and tear film homeostasis, and that it helped tears stay on the eyes for 33% longer

Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.

Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.

Deepak Sambhara, MD, sat down with Ophthalmology Times to discuss the impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME), as a post hoc analysis of the phase 2/3 PHOTON trial.

The UME module adds to the list of ophthalmic diseases available in the dataset.

The company is in the process of seeking regulatory approvals for the lens in the US and Europe.

Abbreviated New Drug Applications seek potential approval of a generic drug product.

The AIOLIS will be used to clinically evaluate patients’ perception of visual disturbances following premium IOL cataract surgery.

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with dry eye disease.

Roy Rubinfeld, MD, MA, discussed EpiSmart cross-linking for keratoconus and the ongoing trials and results at the IKA 2024 Symposium.

At the IKA 2024 Symposium, Michael Belin, MD, discussed the ABCD Progression Display he developed to classify disease severity and help diagnose keratoconus earlier.